Provided are various embodiments relating to variant IgG Fc polypeptides ofcompanion animals having increasedProtein A binding for ease of purification, decreased C1q binding for reducedcomplement-mediated immune responses, decreasedCD16 binding (e.g. , for reduced antibody-dependent cellular cytotoxicity(ADCC) induction, increased stability, and/or the ability toform heterodimeric proteins. In addition, various embodiments relating toantibodies and fusion proteins comprising such variant IgG Fcpolypeptides are provided. Also provided are various embodiments relating tocontiguous polypeptides comprising one or more variantGLP 1 polypeptide(s) having improved serum half-life. Further provided arevarious embodiments relating to contiguous polypeptidesor heterodimeric polypeptides comprising a GLP 1 polypeptide and a glucagonpolypeptide as a dual GLP 1 receptor and glucagonreceptor agonist. In various embodiments, such polypeptides may be used totreat, for example, diabetes, obesity, or related indications,in companion animals, such as canines, felines, and equines.
